Tumorend, LLC is a drug development firm organized about the CM101 technology licensed from Vanderbilt University. The Companyâs first product, having completed a successful Phase I clinical trial, is ready to enter Phase II clinical trials for the treatment of patients with solid organ cancer. The Companyâs first veterinary product had a successful canine safety trial and is ready to enter field trials for dogs with solid organ cancer. Tumorendâs initial product, CM101, targets patients with solid organ cancer, such as prostatic, liver, and refractory (multiple organs). Based on animal work and a published Phase I clinical trial (1) Tumorend believes that CM101 holds great promise and could achieve improvement in efficacy and safety. CM101 advantages appear to include: use of the bodyâs own defenses for initiation of a natural immunological response specifically targeting the tumor neovasculature and surrounding tumor area; low toxicity of the drug; potential to reduce or eliminate the need for toxic chemotherapy in the treatment of solid organ cancer. In a Phase I study cited below (1), 15 patients were treated with three intravenous infusions of CM101. Tumor responses in Phase I trials are rare (1-2%). In this trial 33% of the patients showed definite improvement including a classical Kaposiâs sarcoma with multiple lower extremity lesions, a metastatic adenocarcinoma of the small bowel and a hepatocellular carcinoma. All 15 of these solid organ cancer patients were refractory with very limited life expectancy. The results from this study demonstrated very positive effects in multiple tu
